Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Enrica Antonia Martino, Antonella Bruzzese, Enrico Iaccino, Caterina Labanca, Francesco Mendicino, Selena Mimmi, Eugenio Lucia, Virginia Olivito, Antonino Neri, Fortunato Morabito, Ernesto Vigna & Massimo Gentile. (2023) Belantamab mafodotin in multiple myeloma. Expert Opinion on Biological Therapy 0:0, pages 1-5.
Read now
Read now
Articles from other publishers (3)
Staci L. Haney & Sarah A. Holstein. (2022) Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma. International Journal of Molecular Sciences 24:1, pages 111.
Crossref
Crossref
Zdeněk Adam, Luděk Pour, Marta Krejčí, David Zeman, Zdeněk Řehák, Renata Koukalová, Viera Sandecká, Martin Štork & Zdeněk Král. (2022) Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients. Onkologie 16:Suppl. B, pages 61-82.
Crossref
Crossref
Waqqas Tai, Ahsan Wahab, Diana Franco, Zunairah Shah, Aqsa Ashraf, Qurrat-Ul-Ain Abid, Yaqub Nadeem Mohammed, Darshan Lal & Faiz Anwer. (2022) Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma. Antibodies 11:2, pages 22.
Crossref
Crossref